Navigation Links
Researchers find relief for chronic pain
Date:1/22/2008

Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs. In the new study Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain published in the January 22, 2008 issue of the Proceedings of the National Academy of Sciences (PNAS), researchers suggest that gene therapy for pain might in the future become a treatment alternative for patients with severe chronic pain.

Fifty million Americans suffer from chronic pain. Chronic pain patients often do not experience satisfactory pain relief from available treatments due to poor efficacy or intolerable side effects like extreme sleepiness, mental clouding, and hallucinations, said Dr. Andreas Beutler, MD, principal investigator of the study and Assistant Professor of Medicine/ Hematology And Medical Oncology at Mount Sinai School of Medicine.

Mount Sinai researchers designed a viral vector to carry the prepro-b-endorphin gene into primary sensory neurons in order to activate opiate receptors selectively, in a rat model. The agents were delivered directly into the spinal fluid of rats via a lumbar puncture, or spinal tap with only one injection. Results showed that the rats remained symptom-free for an extended period of time.

Our research found that treating chronic pain with Adeno-Associated Virus vector-based gene therapy allows for pain relief for more than three months after a single injection, targeting selectively the pain gate. The technique worked successfully with opioid- and non-opioid therapeutic genes, said Dr. Beutler. Targeted gene therapy will likely avoid the unwanted side effects associated with opioid painkillers such as morphine. Based on our findings, this targeted gene therapy via lumbar puncture appears to be a promising candidate for bench-to-bedside research that might ultimately be tested in patients with intractable chronic pain, e.g., to help patients suffering from severe pain due to advanced cancer.


'/>"/>

Contact: Mount Sinai Newsroom
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
2. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
3. DOE awards supercomputing time to UCSD, SDSC researchers
4. Argonnes Blue Gene/P to host large cadre of INCITE researchers
5. Researchers Hone in on Cancer Stem Cells for Melanoma
6. Anyone can save a life: Penn researchers lead national efforts to improve CPR quality
7. Researchers find new way to block destructive rush of immune cells
8. U of M researchers create beating heart in laboratory
9. Researchers challenge previous findings regarding widely used asthma treatment
10. UT Health Science Center researchers decoding saliva to detect breast cancer
11. Protein power: Researchers trigger insulin production in diabetic mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... Opelousas, LA (PRWEB) , ... July 23, 2017 ... ... providers to interact, thus improving communication, safety and patient-provider relationships. New tools are ... according to results of the 19th Annual Health Care’s Most Wired® survey, released ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... Florida Pain Relief Group – Melbourne, a practice owned by Physician Partners of ... interventional pain management, Dr. Stern also is certified in pediatrics, emergency medicine and ...
(Date:7/23/2017)... ... ... Viora Ltd., a leading medical aesthetics solutions manufacturer, is ... United States Patent and Trademark Office. The patent applies to treatments with Viora’s ... mechanisms to further increase the efficacy and safety of final treatment results for ...
(Date:7/22/2017)... , ... July 22, 2017 , ... ... year with the majority of patients not requiring pain medication after three months ... Sports Medicine’s Annual Meeting today in Toronto, Ontario, Canada found that those ...
(Date:7/21/2017)... PITTSBURGH, PA (PRWEB) , ... July 21, 2017 , ... ... I use a lot of pleural catheters available on the market," said an inventor ... level of comfort and safety for the patient." , He developed the patent-pending PLEURAL ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
Breaking Medicine Technology: